NCT01673919View on ClinicalTrials.gov

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg iv every 4 weeks, 104 weeks

Trial Locations (4)

34295

Montpellier

75679

Paris

75743

Paris

94275

Le Kremlin-Bicêtre

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01673919 - A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study | Biotech Hunter | Biotech Hunter